Japanese Journal of Clinical Oncology 25:25-31 (1995)
© 1995 Foundation for Promotion of Cancer Research
Efficacy of the Angiogenesis Inhibitor O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on Osteosarcoma Growth and Lung Metastasis in Rats
1 Department of Orthopedic Surgery, Cancer Center, Nara Medical University Kashihara, Nara
2 Department of Oncological Pathology, Cancer Center, Nara Medical University Kashihara, Nara
For reprints and all correspondence: Yoichi Konishi, Department of Oncological Pathology, Cancer Center, Nara Medical University, 840, Shijo-cho, Kashihara, Nara 634
Received September 26, 1994; accepted January 18, 1995
The efficacy of the anti-angiogenic agent, O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470), against primary tumor growth and spontaneous lung metastasis was evaluated experimentally using a transplantable osteosarcoma line in rats previously established in our laboratory. Male Fischer 344 rats bearing the tumor with a high potential for metastasis received intermittent or continuous subcutaneous administrations of AGM-1470. Both treatment regimens resulted in significant inhibitions of spontaneous lung metastasis and primary tumor growth in a dose-dependent manner, with continuous administration of AGM-1470 exerting the most pronounced inhibitory effects on both parameters
Key Words: Rat osteosarcoma • AGM-1470 • Angiogenesis • Metastasis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Fu, M. L. Ponce, M. Thill, P. Yuan, N. S. Wang, and K. G. Csaky Angiogenesis Inhibition and Choroidal Neovascularization Suppression by Sustained Delivery of an Integrin Antagonist, EMD478761 Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 5184 - 5190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, J. Xu, J. Lawler, E. Terwilliger, and S. Parangi Adeno-Associated Virus-Mediated Antiangiogenic Gene Therapy with Thrombospondin-1 Type 1 Repeats and Endostatin Clin. Cancer Res., July 1, 2007; 13(13): 3968 - 3976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wang, G. S. Sheppard, P. Lou, M. Kawai, N. BaMaung, S. A. Erickson, L. Tucker-Garcia, C. Park, J. Bouska, Y.-C. Wang, et al. Tumor Suppression by a Rationally Designed Reversible Inhibitor of Methionine Aminopeptidase-2 Cancer Res., November 15, 2003; 63(22): 7861 - 7869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M A Ghanem, G J van Steenbrugge, M K Sudaryo, R B Mathoera, J M Nijman, and T. H van der Kwast Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma J. Clin. Pathol., February 1, 2003; 56(2): 107 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Eder Jr, J. G. Supko, J. W. Clark, T. A. Puchalski, R. Garcia-Carbonero, D. P. Ryan, L. N. Shulman, J. Proper, M. Kirvan, B. Rattner, et al. Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily J. Clin. Oncol., September 15, 2002; 20(18): 3772 - 3784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Kisker, C. M. Becker, D. Prox, M. Fannon, R. D'Amato, E. Flynn, W. E. Fogler, B. K. L. Sim, E. N. Allred, S. R. Pirie-Shepherd, et al. Continuous Administration of Endostatin by Intraperitoneally Implanted Osmotic Pump Improves the Efficacy and Potency of Therapy in a Mouse Xenograft Tumor Model Cancer Res., October 1, 2001; 61(20): 7669 - 7674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Kerbel Clinical Trials of Antiangiogenic Drugs: Opportunities, Problems, and Assessment of Initial Results J. Clin. Oncol., September 15, 2001; 19(90001): 45s - 51. [Full Text] [PDF]
|
|
|
|
|
|
M. Kaya, T. Wada, T. Akatsuka, S. Kawaguchi, S. Nagoya, M. Shindoh, F. Higashino, F. Mezawa, F. Okada, and S. Ishii Vascular Endothelial Growth Factor Expression in Untreated Osteosarcoma Is Predictive of Pulmonary Metastasis and Poor Prognosis Clin. Cancer Res., February 1, 2000; 6(2): 572 - 577. [Abstract] [Full Text]
|
|